Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY: Ibrutinib vs Temsirolimus in Relapsed/Refractory MCL
NCT01646021Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of ibrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-Free Survival at 48 months. Started Dec 2012; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01646021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646021.